NA
MDGL icon

NewEdge Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

NewEdge Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-70
Closed -$32.1K – 4327
2025
Q3 		$32.1K Hold
70
– – ﹤0.01% 2974
2025
Q2 		$21.2K Hold
70
– – ﹤0.01% 2938
2025
Q1 		$23.2K Hold
70
– – ﹤0.01% 2813
2024
Q4 		$21.6K Hold
70
– – ﹤0.01% 2788
2024
Q3 		$14.9K Hold
70
– – ﹤0.01% 2814
2024
Q2 		$19.6K Sell
70
-9
-11% -$2.14K ﹤0.01% 2631
2024
Q1 		$21.1K Buy
79
+70
+778% +$16.5K ﹤0.01% 2611
2023
Q4 		$2.08K Hold
9
– – ﹤0.01% 3329
2023
Q3 		$1.31K Sell
9
-250
-97% -$47.1K ﹤0.01% 3130
2023
Q2 		$59.8K Buy
259
+150
+138% +$40.6K ﹤0.01% 2033
2023
Q1 		$26.4K Sell
109
-62
-36% -$16.9K ﹤0.01% 2239
2022
Q4 		$50 Buy
+171
New +$16.7K ﹤0.01% 3471
2017
Q3 		– Sell
-57
Closed -$901 – 807
2017
Q2 		$901 Buy
+57
New +$891 ﹤0.01% 1355

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NewEdge Advisors's MDGL Position: Q4 2025 in Review

NewEdge Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 70 shares — an estimated $32.1K sold.

NewEdge Advisors first reported a position in MDGL in Q2 2017 and held it in 13 quarters. The position peaked at $59.8K in Q2 2023. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • NewEdge Advisors reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • NewEdge Advisors sold 70 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $32.1K.
  • NewEdge Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2017 and held it in 13 quarters.
  • NewEdge Advisors's Madrigal Pharmaceuticals position peaked at $59.8K in Q2 2023.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.